Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Yana G NajjarDustin McCurryHuang LinYan LinYan ZangDiwakar DavarArivarasan KarunamurthyJoseph J DrabickRogerio I NevesLisa H ButterfieldMarc S ErnstoffIgor PuzanovJoseph J SkitzkiJennifer BordeauxIlaSri B SummitJehovana O BenderJu Young KimBeiru ChenGhanashyam SarikondaAnil PahujaJennifer TsauZeni AlfonsoChristian LaingJames F PingpankMatthew P HoltzmanCindy SanderAmy RoseHassane M ZarourJoanne M JeterAhmad A TarhiniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Neoadjuvant concurrent HDI and pembrolizumab demonstrated promising clinical activity despite high rates of treatment discontinuation. pCR is a prognostic indicator.See related commentary by Menzies et al., p. 4133.